Gara Jalqabaatti › Myotonic Dystrophy
Qorannoo klinikaalii Myotonic Dystrophy Ameerikaa Keessatti hirmaatuu
Qorannoo 19 Myotonic Dystrophy f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Richmond, VAQorannoo 8
- Rochester, NYQorannoo 7
- Boston, MAQorannoo 4
- Gainesville, FLQorannoo 4
- Los Angeles, CAQorannoo 4
- Cedar Rapids, IAQorannoo 3
Naannoon
- CaliforniaQorannoo 5
- FloridaQorannoo 4
- IowaQorannoo 3
- KansasQorannoo 4
- MassachusettsQorannoo 4
- New YorkQorannoo 8
- North CarolinaQorannoo 4
- PennsylvaniaQorannoo 3
- TexasQorannoo 3
- VirginiaQorannoo 8
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07486934A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 10 hanga 55 · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT06844214Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT07700225Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 3 hanga 17 · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06747884Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT03981575DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Namoota walitti qabaa jiraQorannoo ilaalaa
59 Months · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT05224778Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 0 hanga 17 · Saalaa hunda · Haaromfame 05-Wax-2026 · NCT07630389Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 4 hanga 18 · Dhiroota · Haaromfame 27-Cam-2026 · NCT07608432Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
Namoota walitti qabaa jira
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT06716931Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 88 · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT07505342Study of ATX-01 in Participants With DM1
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 64 · Saalaa hunda · Haaromfame 10-Gur-2026 · NCT06300307Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 23-Ama-2026 · NCT07362875Extracellular RNA Biomarkers of Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 5 fi ol · Saalaa hunda · Haaromfame 24-Sad-2025 · NCT05020002Biomarker Development for Muscular Dystrophies
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 5 fi ol · Saalaa hunda · Haaromfame 24-Sad-2025 · NCT05019625Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Sad-2025 · NCT06075693Long-Term Development of Muscular Dystrophy Outcome Assessments
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 6 hanga 50 · Saalaa hunda · Haaromfame 18-Sad-2025 · NCT05989620Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin hundi · Saalaa hunda · Haaromfame 15-Onk-2025 · NCT00082108Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 6 hanga 45 · Saalaa hunda · Haaromfame 28-Cam-2025 · NCT05004129Myotonic Dystrophy Family Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 21-Sad-2024 · NCT02398786Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.